Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01133873 · ClinicalTrials.gov registry record · Phase 4
Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects
A Phase 4 study, sponsored by Xanodyne Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
NCT01133873 is a Phase 4 study that was terminated before completion, run by Xanodyne Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT01133873, a Phase 4 study, was terminated before completion, sponsored by Xanodyne Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the daily maximum tolerated dose of propoxyphene napsylate in healthy subjects.
Interventions
- DRUG Placebo
- DRUG Propoxyphene napsylate (XP20C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01133873
The ClinicalTrials.gov registry entry for NCT01133873 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xanodyne Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01133873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01133873 about?
NCT01133873 is a clinical study titled "Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects". The purpose of this study is to determine the daily maximum tolerated dose of propoxyphene napsylate in healthy subjects.
What is the current status of trial NCT01133873?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2010-06. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01133873?
The interventions under investigation include: Placebo (DRUG), Propoxyphene napsylate (XP20C) (DRUG).
Who is sponsoring clinical trial NCT01133873?
This trial is sponsored by Xanodyne Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.